2.2 Preterm Labor: Assessment, Tocolysis & Neuroprotection

Definition, Epidemiology & Risk Stratification

Preterm birth (PTB)—defined as delivery occurring between 20 0/7 and 36 6/7 weeks of gestation—is the leading cause of neonatal morbidity and mortality in non-anomalous infants. Inpatient obstetric nurses must rapidly differentiate true progressive preterm labor from benign uterine irritability to prevent inappropriate interventions while ensuring timely administration of fetal rescue bundles.

Clinical Diagnostic Criteria for Preterm Labor

1. Regular uterine contractions: $\ge 4$ contractions every 20 minutes or $\ge 8$ in 60 minutes; AND
2. Documented cervical change: Cervical effacement $\ge 80%$ or cervical dilation $\ge 2\text{--}3\text{ cm}$, or progressive cervical dilation/effacement on serial clinical examinations.

Major Risk Factors for Spontaneous Preterm Birth

• Prior Spontaneous Preterm Birth: The single most powerful clinical predictor. A history of one prior preterm birth confers a 1.5- to 2-fold increased risk; two prior preterm deliveries increase the risk more than 3-fold.
• Short Cervical Length on Ultrasound: Transvaginal ultrasound (TVUS) cervical length <25 mm prior to 24 weeks of gestation.
• Multifetal Gestation: Uterine overdistention triggers accelerated myometrial stretch, early gap junction formation, and premature oxytocin receptor upregulation.
• Infection & Inflammation: Subclinical intra-amniotic infection (chorioamnionitis), bacterial vaginosis, pyelonephritis, or systemic maternal infections triggering pro-inflammatory cytokine release (IL-1, IL-6, TNF-alpha) and downstream prostaglandin cascades.
• Cervical Surgical Procedures: Prior loop electrosurgical excision procedure (LEEP) or cold-knife cone biopsy.
• Short Interpregnancy Interval: Interpregnancy interval <6 to 18 months.
• Demographic & Nutritional Factors: Maternal pre-pregnancy BMI <19.8, maternal smoking, substance use, and severe maternal psychological stress.

---

Diagnostic Evaluation: TVUS Cervical Length & Fetal Fibronectin (fFN)

Accurate diagnosis prevents unnecessary maternal hospital admissions, unneeded tocolysis exposure, and unwarranted medical transfers.

               [ SUSPECTED PRETERM LABOR WORKUP (22 0/7 – 34 6/7 WKS) ]
                                         │
                  ┌──────────────────────┴──────────────────────┐
                  ▼                                             ▼
      [ Speculum Examination First ]                 [ Transvaginal Ultrasound ]
      Collect fFN swab BEFORE digital exam          Measure Cervical Length (CL):
      or lubricant; check ROM / infection           • CL >30 mm: Low risk (PTL unlikely)
                  │                                 • CL <20 mm: High risk (treat PTL)
                  │                                 • CL 20–29 mm: Rely on fFN result
                  └──────────────────────┬──────────────────────┘
                                         │
                                         ▼
                            [ fFN Test Interpretation ]
                                         │
              ┌──────────────────────────┴──────────────────────────┐
              ▼                                                     ▼
    [ Negative fFN (<50 ng/mL) ]                          [ Positive fFN (≥50 ng/mL) ]
    • >95% to 99% Negative Predictive Value              • Low Positive Predictive Value (~20–30%)
    • Patient will NOT deliver in next 7–14 days          • Increased risk of imminent preterm delivery
    • Avoid unnecessary tocolytics / admission           • Administer antenatal steroids & MgSO4 (if <32w)

Fetal Fibronectin (fFN) Testing Protocols

• Biomarker Concept: Fetal fibronectin is an extracellular matrix glycoprotein acting as the "biological glue" between the fetal chorion and maternal decidua. It is normally present in cervicovaginal secretions prior to 20 weeks and again near term (>35 weeks). Its presence between 22 0/7 and 34 6/7 weeks indicates mechanical or inflammatory disruption of the choriodecidual interface.
• Negative Predictive Value (NPV): A negative test (<50 ng/mL) has an exceptional NPV of >95% to 99% for delivery within the subsequent 7 to 14 days. This provides high clinical confidence to withhold tocolytics, avoid hospital admission, and safely discharge the patient.
• Positive Predictive Value (PPV): A positive test (≥50 ng/mL) has a low PPV (~20% to 30%), indicating increased risk but not guaranteeing labor.
• Confounders Producing False-Positive Results:
  • Digital vaginal examination within the preceding 24 hours
  • Sexual intercourse within the preceding 24 hours
  • Moderate to gross vaginal bleeding (maternal fibronectin in blood)
  • Rupture of amniotic membranes
  • Endocervical lubricants, douches, or active vaginal infections

---

Antenatal Corticosteroid Therapy

Antenatal corticosteroids stimulate fetal lung maturation by accelerating the synthesis and release of alveolar surfactant by type II pneumocytes, improving pulmonary compliance, and reducing microvascular permeability in the fetal brain and gastrointestinal tract.

Evidence-Based Clinical Benefits

• Decreases Neonatal Mortality by ~31%
• Decreases Respiratory Distress Syndrome (RDS) by ~34%
• Decreases Intraventricular Hemorrhage (IVH) by ~47%
• Decreases Necrotizing Enterocolitis (NEC) by ~54%

Dosing Regimens & Gestational Windows

Clinical Pearl: Antenatal corticosteroids cause transient maternal hyperglycemia (requiring intensified blood glucose surveillance and insulin titration in diabetic patients) and a temporary decrease in fetal heart rate baseline variability and biophysical profile scores lasting 48 to 72 hours post-administration.

---

Fetal Neuroprotection: Magnesium Sulfate ($MgSO_4$)

• Clinical Objective: Significantly reduces the incidence and severity of cerebral palsy (CP) and gross motor dysfunction in surviving preterm infants when administered prior to imminent preterm birth.
• Gestational Age Indication: Administered between 24 0/7 and 31 6/7 weeks of gestation when birth is anticipated or planned within the next 24 hours (e.g., active labor with cervical dilation $\ge 4\text{ cm}$, planned indicated preterm delivery, or PPROM with regular uterine contractions).
• Standard Neuroprotective Dosing:
  • Loading Dose: 4 to 6 g IV over 20 to 30 minutes.
  • Maintenance Infusion: 1 to 2 g/hr IV continuous infusion.
  • Duration: Continued until delivery or for up to a maximum of 24 hours. If delivery does not occur within 24 hours and is no longer imminent, the infusion is discontinued.

Magnesium Sulfate Toxicity & Nursing Surveillance Protocol

Magnesium is eliminated almost entirely by maternal renal excretion. Impaired renal clearance causes rapid toxic accumulation.

                  [ SERUM MAGNESIUM LEVEL & CLINICAL TOXICITY ]

  4.8 – 8.4 mg/dL   ██████████████████████████████  [ THERAPEUTIC RANGE ]
  (4.0 – 7.0 mEq/L)

  9.6 – 12.0 mg/dL  ████████████████████████████████████  [ LOSS OF PATELLAR DTRs ]
  (8.0 – 10.0 mEq/L)                                    *Earliest clinical sign of toxicity*

  12.0 – 14.4 mg/dL ██████████████████████████████████████████  [ RESPIRATORY DEPRESSION ]
  (10.0 – 12.0 mEq/L)                                         *RR <12 breaths/min*

  >15.0 – 18.0 mg/dL ████████████████████████████████████████████████  [ RESPIRATORY ARREST ]
  (>12.5 mEq/L)

  >20.0 – 25.0 mg/dL ██████████████████████████████████████████████████████  [ CARDIAC ARREST ]
  (>17.0 mEq/L)

• Hourly Nursing Assessments:
  1. Patellar Deep Tendon Reflexes (DTRs): Must be present (+2 normal). Loss of DTRs is the primary early warning sign of impending severe toxicity.
  2. Respiratory Rate: Must remain $\ge 12\text{ breaths/min}$ with continuous pulse oximetry.
  3. Strict Urine Output: Monitored via indwelling Foley catheter; must be $\ge 30\text{ mL/hr}$ (or $\ge 100\text{ mL}$ every 4 hours).
• Emergency Antidote: Calcium Gluconate 1 g IV ($10\text{ mL}$ of a $10%$ solution) administered slowly IV push over 3 to 5 minutes for severe toxicity (respiratory depression, somnolence, cardiac arrhythmias).

---

Tocolytic Pharmacotherapy

The primary clinical purpose of tocolytic therapy is short-term prolongation of pregnancy (up to 48 hours) to allow:

1. Completion of a full course of antenatal corticosteroids;
2. Administration of magnesium sulfate for neuroprotection; and
3. Maternal transport to a tertiary perinatal center with a Level III/IV NICU.

Tocolytics do not directly reduce neonatal mortality and are not indicated for prolonged maintenance.

---

Surgical Interventions: Cervical Cerclage

Cervical cerclage involves placing a purse-string non-absorbable suture around the cervix to provide mechanical support at the level of the internal os.

1. History-Indicated Cerclage: Placed electively at 12 to 14 weeks of gestation for individuals with a classic history of cervical insufficiency ($\ge 1$ second-trimester loss characterized by painless cervical dilation in the absence of labor or placental abruption).
2. Ultrasound-Indicated Cerclage: Placed between 16 0/7 and 23 6/7 weeks in a singleton pregnancy with a history of prior spontaneous preterm birth and current TVUS cervical length <25 mm.
3. Physical Exam-Indicated (Rescue / Emergent) Cerclage: Placed when painless cervical dilation (1 to 4 cm) is discovered on sterile speculum/digital exam between 16 0/7 and 23 6/7 weeks in the absence of active labor, chorioamnionitis, or placental abruption.
4. Cerclage Removal Timing: Electively removed at 36 0/7 to 37 0/7 weeks in the outpatient setting, or removed immediately upon the onset of active labor, suspected chorioamnionitis, or heavy vaginal bleeding to prevent catastrophic cervical laceration or uterine rupture.